Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis

2期 已完成 NCT04921345

摘要

The purpose of this study was to assess the pharmacokinetics (PK), safety, and efficacy of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).

Nemolizumab Serum Concentrations

At Weeks 4, 8, 12, 16, 32 and 52 · nanograms per milliliters (ng/mL)

Apparent Total Body Clearance (Cl/F) of Nemolizumab

Pre-dose at Weeks 4, 8, 12, 16, 32 and 52 · liter per day (L/day)

Apparent Volume of Distribution (Vd/F) of Nemolizumab

Pre-dose at Weeks 4, 8, 12, 16, 32 and 52 · liter

在 BENITIONS 中查看 查看 ClinicalTrials.gov 原文

同一适应症的其他试验

• A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moder — LEO Pharma
• A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis — Eli Lilly and Company
• Aquacel Hypersensitivity Dressing in TJAs — Rush University Medical Center
• A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Par — Amgen
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Amgen
• A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic D — Amgen

全部试验